Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Clin Cancer Res. 2014 Oct 7;20(23):5946–5955. doi: 10.1158/1078-0432.CCR-14-1404

Table 1.

Patient demographics.

ID Age Gender Race ISS Stage at screening B2M Cr Revlimid exposed/refractory Velcade exposed/refractory Number of prior therapies Number of prior lines of therapy Cytogenetics at screening
DL1
A 61 F C 1 2.8 0.9 Y/N Y/N 9 6 ND
B 77 M C 2 3.6 1.1 Y/Y Y/N 7 7 5q+, 19p+, 11q22 tetrasomy
C 48 M C 2 2.6 1.1 Y/N Y/N 5 2 13.q14-, 5q+, 19p+, 11q22 tetrasomy, 1q21+
DL2
D 48 F C 3 8.1 1.7 Y/N Y/N 7 6 13.q14-, 13q34-, 1q21+, 1q23+
E 51 F C 2 4.3 0.8 Y/Y Y/N 9 8 17p13-, 13.q14-, 13q34- 1q21+, 1q23+, 1p36-
F 67 M C 1 2.6 0.9 Y/Y Y/N 5 1 17p13+, 5q+, 19p+, 11q22+, 1q+, t(11;14)
G 60 M C 3 28.9 8.9 Y/N Y/Y 10 9 normal
H 55 F C 2 1.8 0.3 Y/Y Y/N 3 1 normal
I 76 M C 3 9.8 4.3 Y/N Y/N 5 3 normal
J 48 M C 1 1.9 0.8 Y/Y Y/N 5 1 5q+, 19p+
K 61 M C 2 5.3 1.9 Y/N Y/N 5 4 13.q14-, 5q+, 19p+, 11q22+, 12p-, 1q21+, 1q23+, 1p36+
L 62 M AA 1 2.4 1.2 Y/Y Y/Y 5 3 19p+, 11q22+, 12p-, 1q21+, 1q23+, 1p36+*

Patient demographics of all patients enrolled on the phase 1 single agent Reolysin trial. Patient factors included age, gender, and race; ISS stage, beta-2 microglobulin, cytogenetics and serum creatinine at the time of screening; assessment of prior revlimid and/or velcade exposure, and number of prior therapies and lines of therapy. Abbreviations: B2M = beta-2 microglobulin at screening, Cr = serum creatinine at screening; ISS = International Staging System; F = female, M = male; Y = yes, N = no; C = Caucasian, AA = African American; NA = not applicable, ND = not determined; DL1 = dose level 1 (3 × 109 TCID50/day), DL2 = dose level 2 (3 × 1010 TCID50/day).